News about Drug Discovery & Development

Formosa Pharmaceuticals Partners with Singapore Eye Research Institute for Corneal Disease Therapies

Formosa Pharmaceuticals partners with Singapore Eye Research Institute to develop next-generation ophthalmic formulations using APNT nanoparticle technology and advanced clinical research expertise for corneal diseases.

Drug Discovery & Development | 02/05/2026 | By News Bureau

Nagaland University Converts Invasive Plant into Breakthrough for Drugs, Antibacterial and Cancer Research

A research team from Nagaland University has developed an eco-friendly method to convert the invasive plant Mikania micrantha into silver nanoparticles, boosting drug production, antibacterial activity, and promising cancer research without toxic chemicals.

Drug Discovery & Development | 22/04/2026 | By News Bureau

Partner Therapeutics Submits sBLA to FDA for BIZENGRI

Partner Therapeutics submits sBLA to FDA for BIZENGRI in NRG1 fusion-positive cholangiocarcinoma, supported by eNRGy study data showing 36.8 percent response rate and durable efficacy.

Drug Discovery & Development | 15/04/2026 | By News Bureau |  101

Haisco Signs Exclusive Deal with AbbVie to Develop Novel Pain Therapies

Haisco partners with AbbVie to develop novel pain therapies, with multiple compounds in preclinical to Phase 1 stages targeting pain-related conditions.

Drug Discovery & Development | 13/04/2026 | By News Bureau |  105

Artivion Secures US FDA Approval for Endospan's NEXUS Aortic Arch System

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that the US Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the NEXUS Aortic Arch System, developed by Endospan Ltd. (Endospan), Artivion's long-standing partner.

Drug Discovery & Development | 08/04/2026 | By Darshana

Concept Medical Unveils Landmark SirPAD Trial at ACC 2026, Advancing PAD Treatment

Concept Medical Inc. (CMI), a global leader in drug-delivery technologies for vascular interventions, has announced the presentation of the world’s largest randomized controlled trial evaluating a sirolimus-coated balloon (SCB) for peripheral artery disease (PAD) at the ACC 2026 Scientific Sessions.

Drug Discovery & Development | 01/04/2026 | By Darshana |  128

Wockhardt's Zaynich Gets CDSCO SEC Nod for Gram-Negative Infections

CDSCO’s Subject Expert Committee (SEC) recommends Wockhardt’s Zaynich (Zidebactam/Cefepime) for Gram-negative infections, paving the way for DCGI approval of the novel antibiotic in India.

Drug Discovery & Development | 30/03/2026 | By News Bureau |  149

Takeda's Zasocitinib Shows Strong Skin Clearance in Psoriasis Study

Takeda reports Phase 3 data showing zasocitinib delivers rapid, durable skin clearance in psoriasis, with ~70 percent achieving sPGA 0/1 and early PASI 75 response, with a consistent safety profile.

Drug Discovery & Development | 30/03/2026 | By News Bureau |  116

PharmaJet, REDE-TB to Launch Clinical Study on Needle-Free TB Skin Testing Technology

The study will evaluate accuracy, safety and patient acceptance of needle-free Tropis system compared to traditional tuberculin skin test

Drug Discovery & Development | 26/03/2026 | By News Bureau

LB Pharmaceuticals Starts Phase 3 Trial for LB-102 in Schizophrenia

LB Pharmaceuticals initiates Phase 3 NOVA-2 trial of LB-102 for schizophrenia, enrolling ~460 patients to assess PANSS score, symptoms and safety, with topline results expected in 2H 2027.

Drug Discovery & Development | 26/03/2026 | By News Bureau |  136